Ingredient or product comparison
[Comparison Table] GHK-Cu vs Standard Joint Therapies
The table below compares GHK-Cu to conventional arthritis treatments across key clinical parameters. GHK-Cu NF-κB suppression, cytokine reduction (TNF-α, IL-6) Stimulates collagen synthesis via TGF-β1, increases aggrecan production Minimal. Local irritation wi
This source-based comparison does not add ratings or recommend a winner.
- The table below compares GHK-Cu to conventional arthritis treatments across key clinical parameters.
- GHK-Cu
- NF-κB suppression, cytokine reduction (TNF-α, IL-6)
- Stimulates collagen synthesis via TGF-β1, increases aggrecan production
- Minimal. Local irritation with topical use, no systemic toxicity reported
- Topical cream, intra-articular injection, subcutaneous
- Phase II human trials, extensive in vitro data
- Adjunct for OA, investigational for RA
- NSAIDs (ibuprofen, naproxen)
- COX enzyme inhibition, prostaglandin reduction
- None. May impair cartilage repair at high doses
- GI bleeding, cardiovascular risk, renal impairment with chronic use
- Oral
- FDA-approved, widespread clinical use
- First-line for pain management
- Corticosteroids (triamcinolone, methylprednisolone)
- Broad glucocorticoid receptor activation, cytokine suppression
- Negative. Inhibits chondrocyte activity, accelerates cartilage loss with repeat injections
- Cartilage degradation, infection risk, systemic effects (hyperglycemia, osteoporosis)
- Intra-articular injection
- FDA-approved, standard of care for flares
- Acute flare management, limited to 3–4 injections/year
- Hyaluronic acid (viscosupplementation)
- Minimal direct anti-inflammatory effect
- Mechanical lubrication, modest chondroprotective signaling
- Injection site pain, rare septic arthritis
- Intra-articular injection (series of 3–5)
- Mixed evidence. Some RCTs show benefit, others null
- OA management when NSAIDs fail
- Glucosamine/Chondroitin
- Weak anti-inflammatory activity
- Proposed chondroprotective effect, inconsistent evidence
- Well-tolerated, rare GI upset
- Mixed. Some trials positive, Cochrane review inconclusive
- OTC supplementation, variable efficacy
- DMARDs (methotrexate, biologics)
- Immune suppression, cytokine blockade (TNF-α inhibitors, IL-6 inhibitors)
- Indirect. Prevents further damage, no direct repair
- Serious infections, hepatotoxicity, bone marrow suppression
- Oral, subcutaneous, IV infusion
- FDA-approved for RA, PsA
- Disease modification in autoimmune arthritis